Immunotherapy in Recurrent Ovarian Cancer
- User
Immunotherapy in Recurrent Ovarian Cancer
- Assistant
Immunotherapy is an emerging approach in the treatment of recurrent ovarian cancer, aiming to harness the body's immune system to combat cancer cells. Several immunotherapeutic strategies are under investigation, including immune checkpoint inhibitors, oncolytic viruses, and cancer vaccines.
Immune Checkpoint Inhibitors
Immune checkpoint inhibitors are designed to block proteins that inhibit the immune response, thereby enhancing the body's ability to fight cancer. Dostarlimab, a PD-1 inhibitor, has been approved for the treatment of recurrent or advanced endometrial cancer with mismatch repair deficiency (dMMR). While its primary approval is for endometrial cancer, ongoing research is exploring its efficacy in other solid tumors, including ovarian cancer[1].
Oncolytic Viruses
Oncolytic viruses selectively infect and destroy cancer cells. Enadenotucirev is an oncolytic adenovirus that has undergone clinical trials for epithelial solid tumors. The OCTAVE trial specifically investigated its use in ovarian cancer patients, assessing safety and therapeutic potential[2].
Cancer Vaccines
Cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells. Abagovomab is a monoclonal antibody that mimics the CA-125 tumor antigen, prevalent in ovarian cancer. Although initial studies showed promise, a Phase III trial did not demonstrate a significant benefit in delaying ovarian cancer progression[3].
Recent Developments
In June 2024, AbbVie announced that its therapy, Elahere, met the primary goal in a mid-stage trial for patients with ovarian, fallopian tube, or abdominal wall cancer who had received at least two prior treatments. Elahere is an antibody-drug conjugate that targets cancer cells, potentially reducing toxicity to other cells. It received FDA approval in March 2024 for patients with similar conditions who had undergone up to three prior treatments[4].
While these advancements are promising, immunotherapy for recurrent ovarian cancer remains an area of active research. Patients should consult with their healthcare providers to discuss the most current and appropriate treatment options available.
AbbVie's Ovarian Cancer Therapy Shows Promise in Mid-Stage Trial:
- AbbVie's ovarian cancer therapy succeeds in mid-stage trial[4]
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.